Shenzhen-based META Pharmaceuticals Inc., a developer of immuno-metabolism targeted small molecules, has reportedly raised RMB 100 million (USD 14.8 million) in seed and Pre-Series A financing rounds. The funding was led by Forcefield Ventures, XtalPi, IMO Ventures, and Tiantu Capital, with participation from FountainVest Partners, Decent Investment, Yael Capital, New Industry Venture Capital, and Bopu Fund. Proceeds will support clinical studies for three small molecules, development of an AI metabolic enzyme target discovery platform, and the establishment of a biology laboratory in Shenzhen.
Company Background and Progress
META Pharmaceuticals was incubated by Forcefield Ventures and XtalPi in August 2021. The company boasts founders from prestigious institutions such as Weill Cornell Medicine and Memorial Sloan Kettering Cancer Center. Focused on autoimmune diseases, META is advancing three potential first-in-class programs, with plans to file for clinical trials in the US and China in 2024.-Fineline Info & Tech
